Dr. Joe McCord, the chief science officer behind Protandim is is known for the monumental discovery of the antioxidant Superoxide Dismutase (SOD) in 1969, which serves as the foundation upon which our understanding of how antioxidants and free radicals work in the human body. Dr. McCord has received many awards and honors for his research and discoveries of the biology of free radical reactions in living organisms. For this work Dr. McCord received the Elliot Cresson Medal of the Franklin Institute. In 1997 Dr. McCord received a lifetime achievement award from the Oxygen Society for outstanding contributions to the field of free radical biology and medicine.
Dr. McCord academic background includes a B.S. degree in chemistry from Rhodes College (graduated 1966) and a Ph.D. in biochemistry from Duke University (graduated 1970), where he also conducted postdoctoral research. Dr. McCord is a past recipient of the Elliott Cresson Medal, the Discovery Award from the Society for Free Radical Biology and Medicine (SFRBM), and a Lifetime Achievement Award from the Oxygen Society. He holds an Honorary Doctorate from the University of Buenos Aires and has served as Honorary President of the International Society of Antioxidants in Nutrition and Health (ISANH) and as Chairman of the Third International Conference on Superoxide Dismutases at the Institute Pasteur.
Dr. McCord’s career is distinguished for bridging the gap from basic science to clinical relevance by showing the application of SOD to human physiology, and characterizing the physiological functions of superoxide in inflammation, immune defenses, and injury’s, among other disease conditions. Recognized as a Redox Pioneer has been cited over 1000 times and has published more than 200 articles in scientific books and periodicals, many that can be found at PubMed.gov is a government agency that publishes these peer review studies.
2014 University of Kentucky : Dr. Joe McCord (Ph.D. 1970)
Recognized here as a Redox Pioneer because he has published at least three articles on antioxidant/redox biology as first/last author that have been cited over 1000 times and has published at least 37 articles each cited over 100 times. Dr. McCord is known for the monumental discovery of the antioxidant superoxide dismutase (SOD) while a graduate student under fellow redox pioneer Irwin Fridovich and demonstrating its necessity to aerobic life.
Keap1/Nrf2/ARE plays a key role in maintenance of cellular homeostasis under stress, inflammatory, carcinogenic, and proapoptotic conditions, which allows us to consider it as a pharmacological target. Here we review the basic regulatory mechanisms of the Keap1/Nrf2/ARE system, key targets for pharmacological intervention, and interconnection of this system with other redox-sensitive transcriptional factors. We also discuss the range of currently available pharmaceuticals. Finally, we promote “indirect” antioxidants as a promising strategy for prevention and treatment of wide range of diseases associated with oxidative stress.
2013 Colorado State University : Nrf2 activation: a potential strategy for the prevention of acute mountain sickness.
Of nine drugs tested, with the exception of dexamethasone, only drugs that showed the ability to activate Nrf2 (Protandim, methazolamide, nifedipine, amlodipine, ambrisentan, and sitaxentan) decreased high-altitude-induced cerebral vascular leak in vivo.
2013 Colorado State University : Upregulation of phase II enzymes
Through phytochemical activation of Nrf2 protects cardiomyocytes against oxidant stress.Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcriptional regulator of phase II antioxidant enzymes, and activation of Nrf2 has been suggested to be an important step in attenuating oxidative stress associated with cardiovascular disease.
2012 University of Connecticut : Nuclear erythroid 2–related factor 2 (Nrf2) is an oxidative stress–mediated transcription factor
With a variety of downstream targets aimed at cytoprotection. Nrf2 has recently been implicated as a new therapeutic target for the treatment of liver disease.
2012 University of Colorado : Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge.
Activation of NF-E2-related factor 2 (Nrf2) is a potential therapeutic intervention against endothelial cell oxidative stress and associated vascular disease. We hypothesized that treatment with the phytochemicals in the patented dietary supplement Protandim would induce Nrf2 nuclear localization and phase II antioxidant enzyme protein in human coronary artery endothelial cells (HCAECs), protecting against an oxidant challenge in an Nrf2- dependent manner.
2012 University of Colorado : Protandim does not influence alveolar epithelial permeability or intrapulmonary oxidative stress in human subjects with alcohol use disorders
Including alcohol abuse and dependence, have been linked to the development of acute lung injury (ALI). Prior clinical investigations suggested an association between AUDs and abnormal alveolar epithelial permeability mediated through pulmonary oxidative stress thatmay partially explain this relationship.
2011 European and Americas Committees for Treatment and Research in Multiple Sclerosis Amsterdam, Netherlands
Nrf2 activators: a novel strategy to promote oligodendrocyte survival in multiple sclerosis? Potential of different Nrf2 activators to boost antioxidant enzyme expression in oligodendrocytes and protect them from reactive oxygen species (ROS)-mediated cell death.
2011 University of Colorado : Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation.
In the last decade our view of oxidative stress has broadened considerably, and it is now often seen as an imbalance that has its origins in our genes, and the ways in which gene expression is regulated. At the center of this new focus is the transcription factor called nuclear factor (erythroid-derived 2)-like 2, or Nrf2. Nrf2 is referred to as the “master regulator” of the antioxidant response. Protandim is an antioxidant supplement that consists of five ingredients, namely, ashwagandha, bacopa extract, green tea extract, silymarin, and curcumin, each with known therapeutic properties. Download PDF
2011 Louisiana State University : The Role of Manganese Superoxide Dismutase in Skin Cancer.
This method effectively reduced oxidative injury and proliferation without interfering with apoptosis. In another approach, Protandim, a combination of 5 well-studied medicinal plants, was given via dietary administration and significantly decreased tumor incidence and multiplicity by 33% and 57%, respectively. These studies suggest that alterations in antioxidant response may be a novel approach to chemoprevention.
2011 Ohio State University : Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway
Treatment of HSV during culture with Protandim increased the activity of SOD, HO-1, and catalase 3-, 7-, and 12-fold, respectively, and decreased the levels of superoxide (O(2)(•-)) and the lipid peroxidation product 4-HNE.
2010 University of Colorado : The Dietary Supplement Protandim Decreases Plasma Osteopontin
Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice. In this study we investigated whether Protandim provided benefit using surrogate markers and functional measures in the dystrophin-deficient (mdx)mouse model of DMD. After 6 months of Protandim, a 48% average decrease in plasma TBARS was seen.
Previous studies have demonstrated that Protandim suppresses cutaneous proliferation and inflammation. Since DMBA/TPA also causes cell death, we investigated the effects of Protandim on cutaneous apoptosis. Download PDF
2009 American Heart Association : Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure.
Pulmonary hypertension and subsequent right heart failure are increasingly being identified as worldwide problems affecting patients with highly prevalent diseases such as schistosomiasis, sickle cell disease, HIV infection, chronic obstructive pulmonary disease, and chronic left heart failure.1 Right ventricular (RV) function is the most important determinant of longevity in patients with pulmonary arterial hypertension. Download PDF
2009 Louisiana State University : Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention
Using Mouse Two-Stage Skin Carcinogenesis as a Model. At the end of the carcinogenesis study both skin tumor incidence and multiplicity were reduced in the mice on the Protandim diet by 33% and 57% respectively, compared with those on basal diet.studies revealed that the Protandim diet suppressed tumor promoter-induced oxidative stress (evidenced by reduction of protein carbonyl levels). Protandim may serve as a practical and potent approach for cancer prevention. Download PDF
2009 University of Colorado : Synergistic induction of heme oxygenase-1 by the components of the antioxidant supplement Protandim.
Protandim is an antioxidant supplement that consists of five ingredients, namely, ashwagandha, bacopa extract, green tea extract, silymarin, and curcumin, each with known therapeutic properties. There were significant increases in the levels of total glutathione in Protandim-treated cells. These findings suggest that the use of a combination of phytochemicals may be an efficient method for the induction of antioxidant enzymes. Download PDF
2006 University of Colorado: The induction of human superoxide dismutase and catalase in vivo
a fundamentally new approach to antioxidant therapy. five widely studied medicinal plants (Protandim) was administered to healthy human subjects ranging in age from 20 to 78 years. Download PDF
1985 University of Colorado : Oxygen-derived free radicals in postischemic tissue injury
Dysfunction induced by free radicals may thus be a major component of ischemic diseases of the heart, bowel, liver, kidney, and brain. Read Article. Download PDF